<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
        <PMID Version="1">23112977</PMID>
        <DateCreated>
            <Year>2012</Year>
            <Month>10</Month>
            <Day>31</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2012</Year>
            <Month>11</Month>
            <Day>01</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>05</Month>
            <Day>30</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1947-2714</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>4</Volume>
                    <Issue>10</Issue>
                    <PubDate>
                        <Year>2012</Year>
                        <Month>Oct</Month>
                    </PubDate>
                </JournalIssue>
                <Title>North American journal of medical sciences</Title>
                <ISOAbbreviation>N Am J Med Sci</ISOAbbreviation>
            </Journal>
            <ArticleTitle>CD45/CD8 Myeloid Histioid Antigen and Plasma Cell Antibody Immune Response in a Case of Malignant Melanoma.</ArticleTitle>
            <Pagination>
                <MedlinePgn>507-9</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.4103/1947-2714.102006</ELocationID>
            <Abstract>
                <AbstractText>The immune response in metastatic melanoma is not well established and therefore is of particular interest to test for recruitment of immune cells to the tumor. A 46-year-old Caucasian female was evaluated for an asymptomatic right forearm mass. The lesion had been present for at least 4 years and had become painful 4 months ago. Biopsies for hematoxylin and eosin (H and E) staining, as well as immunohistochemical analysis were performed on the primary tumor and on sentinel lymph nodes. The H and E staining was consistent with metastatic melanoma. Positive staining was noted on the tumor cells with S-100, Mart-1/Melan A/CD63, PNL2, HMB45, and tyrosinase. Peritumoral and intratumoral inflammatory cells stained positive for CD8, CD45, PCNA, myeloid histoid antigen, antihuman plasma cell antibody, and focal BRCA1. The staining patterns of CD8/CD45, myeloid histoid antigen and plasma cell antibody on inflammatory cells around the melanoma cells suggest an unusual type of immune response.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Abreu-Velez</LastName>
                    <ForeName>Ana Maria</ForeName>
                    <Initials>AM</Initials>
                    <Affiliation>Georgia Dermatopathology Associates, Atlanta, USA.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Howard</LastName>
                    <ForeName>Michael S</ForeName>
                    <Initials>MS</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Pereyo</LastName>
                    <ForeName>Neville Y</ForeName>
                    <Initials>NY</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Delman</LastName>
                    <ForeName>Keith A</ForeName>
                    <Initials>KA</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mihm</LastName>
                    <ForeName>Martin C</ForeName>
                    <Initials>MC</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Rizzo</LastName>
                    <ForeName>Monica</ForeName>
                    <Initials>M</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>India</Country>
            <MedlineTA>N Am J Med Sci</MedlineTA>
            <NlmUniqueID>101521411</NlmUniqueID>
            <ISSNLinking>1947-2714</ISSNLinking>
        </MedlineJournalInfo>
        <CommentsCorrectionsList>
            <CommentsCorrections RefType="Cites">
                <RefSource>Lab Invest. 2003 Nov;83(11):1555-67</RefSource>
                <PMID Version="1">14615410</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Arch Dermatol. 2004 Jan;140(1):99-103</RefSource>
                <PMID Version="1">14732666</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cancer Res. 2006 Apr 1;66(7):3629-38</RefSource>
                <PMID Version="1">16585188</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Clin Oncol. 2008 Feb 1;26(4):535-41</RefSource>
                <PMID Version="1">18235114</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Arch Dermatol. 2008 Jan;144(1):49-56</RefSource>
                <PMID Version="1">18209168</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Arch Dermatol Res. 2009 Oct;301(10):711-8</RefSource>
                <PMID Version="1">19547994</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Cutan Pathol. 2010 Feb;37(2):222-30</RefSource>
                <PMID Version="1">19615020</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Eur J Dermatol. 2010 Jan-Feb;20(1):74-81</RefSource>
                <PMID Version="1">19889592</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Clin Oncol. 2009 Jul 20;27(21):3489-95</RefSource>
                <PMID Version="1">19451446</PMID>
            </CommentsCorrections>
        </CommentsCorrectionsList>
        <OtherID Source="NLM">PMC3482787</OtherID>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">CD45</Keyword>
            <Keyword MajorTopicYN="N">CD8</Keyword>
            <Keyword MajorTopicYN="N">Immune response</Keyword>
            <Keyword MajorTopicYN="N">Metastatic melanoma</Keyword>
            <Keyword MajorTopicYN="N">Myeloid histiod antigen</Keyword>
            <Keyword MajorTopicYN="N">Plasma cell antibody</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2012</Year>
                <Month>11</Month>
                <Day>1</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2012</Year>
                <Month>11</Month>
                <Day>1</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2012</Year>
                <Month>11</Month>
                <Day>1</Day>
                <Hour>6</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.4103/1947-2714.102006</ArticleId>
            <ArticleId IdType="pii">NAJMS-4-507</ArticleId>
            <ArticleId IdType="pubmed">23112977</ArticleId>
            <ArticleId IdType="pmc">PMC3482787</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>
